L-type Ca2+ channel density and regulation are altered in failing human ventricular myocytes and recover after support with mechanical assist devices

Circulation Research

Volumn 91, Issue 6, 2002, Pages 517-524

  Chen, Xiongwen ^a   Piacentino III, Valentino ^a   Furukawa, Satoshi ^a   Goldman, Bruce ^a   Margulies, Kenneth B ^a   Houser, Steven R ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Heart failure; L type calcium channel; Left ventricle assist device; PKA dependent phosphorylation

Indexed keywords

CALCIUM CHANNEL L TYPE; CYCLIC AMP DEPENDENT PROTEIN KINASE; 1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUCLADESINE; CALCIUM CHANNEL STIMULATING AGENT; ENZYME INHIBITOR; ISOPRENALINE; OKADAIC ACID; PHOSPHOPROTEIN PHOSPHATASE;

ARTICLE; BETA ADRENERGIC STIMULATION; CALCIUM CURRENT; CALCIUM TRANSPORT; ENZYME PHOSPHORYLATION; EXCITATION CONTRACTION COUPLING; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE; HEART MUSCLE CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RECEPTOR DENSITY; SARCOPLASMIC RETICULUM; SODIUM CALCIUM EXCHANGE; CELL MEMBRANE POTENTIAL; CONGESTIVE HEART FAILURE; DRUG ANTAGONISM; DRUG EFFECT; HEART ASSIST DEVICE; HEART VENTRICLE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHOSPHORYLATION;

3-PYRIDINECARBOXYLIC ACID, 1,4-DIHYDRO-2,6-DIMETHYL-5-NITRO-4-(2-(TRIFLUOROMETHYL)PHENYL)-, METHYL ESTER; ADRENERGIC BETA-AGONISTS; BUCLADESINE; CALCIUM CHANNEL AGONISTS; CALCIUM CHANNELS, L-TYPE; CYCLIC AMP-DEPENDENT PROTEIN KINASES; ENZYME INHIBITORS; HEART FAILURE, CONGESTIVE; HEART VENTRICLES; HEART-ASSIST DEVICES; HUMANS; ISOPROTERENOL; MEMBRANE POTENTIALS; MIDDLE AGED; OKADAIC ACID; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHORYLATION;

EID: 0037144097     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000033988.13062.7C     Document Type: Article

References (44)

1. Gwathmey JK, Copelas L, MacKinnon R, Schoen FJ, Feldman MD, Grossman W, Morgan JP. Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res. 1987; 61:70-76.
2. Hajjar RJ, Muller FU, Schmitz W, Schnabel P, Bohm M. Molecular aspects of adrenergic signal transduction in cardiac failure. J Mol Med. 1998;76:747-755.
3. Port JD, Bristow MR. Altered β-adrenergic receptor gene regulation and signaling in chronic heart failure. J Mol Cell Cardiol. 2001;33:887-905.
4. Dipla K, Mattiello JA, Jeevanandam V, Houser SR, Margulies KB. Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure. Circulation. 1998;97:2316-2322.
5. 2+ cycling proteins and Gαq signaling after left ventricular assist device support in failing human hearts. Cardiovasc Res. 2000;45:883-888.
6. Heerdt PM, Holmes JW, Cai B, Barbone A, Madigan JD, Reiken S, Lee DL, Oz MC, Marks AR, Burkhoff D. Chronic unloading by left ventricular assist device reverses contractile dysfunction and alters gene expression in end-stage heart failure. Circulation. 2000;102:2713-2719.
7. Houser SR, Piacentino V III, Weisser J. Abnormalities of calcium cycling in the hypertrophied and failing heart. J Mol Cell Cardiol. 2000;32: 1595-1607.
8. Beuckelmann DJ, Nabauer M, Erdmann E. Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation. 1992;85:1046-1055.
9. i-transients in human myocytes. Basic Res Cardiol. 1997;92(suppl 1):105-110.
10. Gwathmey JK, Slawsky MT, Hajjar RJ, Briggs GM, Morgan JP. Role of intracellular calcium handling in force-interval relationships of human ventricular myocardium. J Clin Invest. 1990;85:1599-1613.
11. Choi DJ, Rockman HA. β-Adrenergic receptor desensitization in cardiac hypertrophy and heart failure. Cell Biochem Biophys. 1999;31:321-329.
12. Ogletree-Hughes ML, Stull LB, Sweet WE, Smedira NG, McCarthy PM, Moravec CS. Mechanical unloading restores β-adrenergic responsiveness and reverses receptor downregulation in the failing human heart. Circulation. 2001;104:881-886.
13. Fabiato A. Calcium-induced release of calcium from the cardiac sarcoplasmic reticulum. Am J Physiol. 1983;245:C1-C14.
14. Mukherjee R, Spinale FG. L-type calcium channel abundance and function with cardiac hypertrophy and failure: a review. J Mol Cell Cardiol. 1998;30:1899-1916.
15. Houser SR. Reduced abundance of transverse tubules and L-type calcium channels: another cause of defective contractility in failing ventricular myocytes. Cardiovasc Res. 2001;49:253-256.
16. 2+ channels in canine tachycardia-induced heart failure. Cardiovasc Res. 2001;49:298-307.
17. Schroder F, Handrock R, Beuckelmann DJ, Hirt S, Hullin R, Priebe L, Schwinger RH, Weil J, Herzig S. Increased availability and open probability of single L-type calcium channels from failing compared with nonfailing human ventricle. Circulation. 1998;98:969-976.
18. 2+ transient of failing human ventricular myocytes. Circ Res. 1999;84:435-444.
19. 2+ release. J Physiol. 2000;523:533-548.
20. Sanguinetti MC, Krafte DS, Kass RS. Voltage-dependent modulation of Ca channel current in heart cells by Bay K8644. J Gen Physiol. 1986; 88:369-392.
21. Zafeiridis A, Jeevanandam V, Houser SR, Margulies KB. Regression of cellular hypertrophy after left ventricular assist device support. Circulation. 1998;98:656-662.
22. 2+ channels in bovine adrenal chromaffin cells. Pflugers Arch. 1992;420:61-71.
23. McDonald TF, Pelzer S, Trautwein W, Pelzer DJ. Regulation and modulation of calcium channels in cardiac, skeletal, and smooth muscle cells. Physiol Rev. 1994;74:365-507.
24. Ouadid H, Albat B, Nargeot J. Calcium currents in diseased human cardiac cells. J Cardiovasc Pharmacol. 1995;25:282-291.
25. Sun H, Leblanc N, Nattel S. Mechanisms of inactivation of L-type calcium channels in human atrial myocytes. Am J Physiol. 1997;272:H1798-H1803.
26. Scamps F, Mayoux E, Charlemagne D, Vassort G. Calcium current in single cells isolated from normal and hypertrophied rat heart: effects of β-adrenergic stimulation. Circ Res. 1990;67:199-208.
27. Bristow MR, Hershberger RE, Port JD, Gilbert EM, Sandoval A, Rasmussen R, Cates AE, Feldman AM. β-Adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation. 1990;82: 112-125.
28. iα in human hearts with dilated but not ischemic cardiomyopathy. Circulation. 1990;82:1249-1265.
29. Neumann J, Eschenhagen T, Jones LR, Linck B, Schmitz W, Scholz H, Zimmermann N. Increased expression of cardiac phosphatases in patients with end-stage heart failure. J Mol Cell Cardiol. 1997;29:265-272.
30. Urasawa K, Yoshida I, Takagi C, Onozuka H, Mikami T, Kawaguchi H, Kitabatake A. Enhanced expression of β-adrenergic receptor kinase 1 in the hearts of cardiomyopathic Syrian hamsters, BIO53.58. Biochem Biophys Res Commun. 1996;219:26-30.
31. Bodor GS, Oakeley AE, Allen PD, Crimmins DL, Ladenson JH, Anderson PA. Troponin I phosphorylation in the normal and failing adult human heart. Circulation. 1997;96:1495-1500.
32. Marx SO, Reiken S, Hisamatsu Y, Jayaraman T, Burkhoff D, Rosemblit N, Marks AR. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell. 2000;101:365-376.
33. Scriven DR, Dan P, Moore ED. Distribution of proteins implicated in excitation-contraction coupling in rat ventricular myocytes. Biophys J. 2000;79:2682-2691.
34. Puri TS, Gerhardstein BL, Zhao XL, Ladner MB, Hosey MM. Differential effects of subunit interactions on protein kinase A- and C-mediated phosphorylation of L-type calcium channels. Biochemistry. 1997;36: 9605-9615.
35. duBell WH, Lederer WJ, Rogers TB. Dynamic modulation of excitationcontraction coupling by protein phosphatases in rat ventricular myocytes. J Physiol (Lond). 1996;493:793-800.
36. Simmerman HK, Jones LR. Phospholamban. protein structure, mechanism of action, and role in cardiac function. Physiol Rev. 1998;78:921-947.
37. 2+-handling in failing human myocardium. J Mol Cell Cardiol. 2001;33:1345-1353.
38. Ferrari R, Ceconi C, Curello S, Visioli O. The neuroendocrine and sympathetic nervous system in congestive heart failure. Eur Heart J. 1998;19(suppl F):F45-F51.
39. 2+ channels. J Physiol (Lond). 1995;484:583-592.
40. Rasmussen RP, Minobe W, Bristow MR. Calcium antagonist binding sites in failing and nonfailing human ventricular myocardium. Biochem Pharmacol. 1990;39:691-696.
41. 2+-channel in myocardium from patients with end-stage heart failure and in non-failing human hearts. Am J Cardiol. 1999;83:507-514.
42. 2+ channel) and calsequestrin genes in the myocardium of patients with end-stage heart failure. J Clin Invest. 1992;90:927-935.
43. Perez-Reyes E, Schneider T. Molecular biology of calcium channels. Kidney Int. 1995;48:1111-1124.
44. Gomez AM, Valdivia HH, Cheng H, Lederer MR, Santana LF, Cannell MB, McCune SA, Altschuld RA, Lederer WJ. Defective excitation-contraction coupling in experimental cardiac hypertrophy and heart failure. Science. 1997;276:800-806.